Acute Lymphocytic Leukemia

Oncology
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Leadiant Biosciences
Leadiant BiosciencesMD - Rockville
1 program
1
DNRPhase 21 trial
Active Trials
NCT02043587Terminated31Est. Apr 2022
UP
UCB PharmaBelgium - Brussels
1 program
1
Inotuzumab OzogamicinPhase 2ADC
E
EisaiChina - Liaoning
1 program
1
DecitabinePhase 11 trial
Active Trials
NCT00349596Completed40Est. Oct 2014
Pfizer
PfizerNEW YORK, NY
1 program
BESPONSA Injection 1 mg Special InvestigationN/A1 trial
Active Trials
NCT05923112Completed421Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Leadiant BiosciencesDNR
EisaiDecitabine
PfizerBESPONSA Injection 1 mg Special Investigation

Clinical Trials (3)

Total enrollment: 492 patients across 3 trials

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Start: Jan 2014Est. completion: Apr 202231 patients
Phase 2Terminated

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Start: Jul 2006Est. completion: Oct 201440 patients
Phase 1Completed
NCT05923112PfizerBESPONSA Injection 1 mg Special Investigation

BESPONSA Injection 1 mg Special Investigation

Start: Jul 2018Est. completion: Sep 2024421 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space